Letter to the Editor: No immunophenotyping in peripheral blood of prostate cancer patients treated with neoadjuvant Rituximab?
J Transl Med
.
2020 Sep 1;18(1):333.
doi: 10.1186/s12967-020-02496-5.
Authors
Paulius Bosas
1
,
Gintaras Zaleskis
2
,
Vita Pasukoniene
3
4
,
Feliksas Jankevicius
1
Affiliations
1
Medical Faculty, Vilnius University, Vilnius, Lithuania.
2
Laboratory of Immunology, National Cancer Institute, P. Baublio 3b, Vilnius, Lithuania. gintaras.zaleskis@nvi.lt.
3
Laboratory of Immunology, National Cancer Institute, P. Baublio 3b, Vilnius, Lithuania.
4
Vilnius Gediminas Technical University, Vilnius, Lithuania.
PMID:
32873304
PMCID:
PMC7466421
DOI:
10.1186/s12967-020-02496-5
No abstract available
Publication types
Letter
MeSH terms
Humans
Immunophenotyping
Male
Neoadjuvant Therapy*
Prostatic Neoplasms* / drug therapy
Rituximab / therapeutic use
Substances
Rituximab